Simon Kohl (@saakohl) / X

Pinned

Today we're launching Latent-Y: the world's first autonomous agent for drug design, lab-validated end to end. Give it a research goal. Latent-Y reasons, designs, iterates, and delivers lab-ready antibodies, autonomously or collaboratively, with the biological reasoning of a PhD

00:00

We have offices in SF and London, and hiring has significantly longer lead times in the UK. I am one of the early signatories in a letter to the Primer Minister @andyburnham asking to improve this. The UK is an amazing place for innovation and has incredible talent. To fully

Inherent

@inherent_labs

Sep 29

1/ Today we’re launching an open letter calling on the government to end unfair restrictions that stop Britain’s best switching jobs or starting companies. UK AI companies that have raised $5bn agree: our best should be free to start and scale. 🧵 @downingstreet @biztradegovuk

On 20 August we're marking the launch of the Latent-Y Researcher Tier with an evening in San Francisco. We opened it to researchers worldwide in July, putting Latent-Y, our drug design agent, in their hands with a daily quota of designs. It's already clear what that makes

Latent-Y Research Tier - Latent Labs

Today we launch Latent-Y, our drug design agent. 250 designs free every day for any approved researcher. We are also releasing the first lab results from researchers with early access: Ion channel inhibitors that work. CAR-T cells that kill tumour cells, now in vivo. Binders the

00:00

Join us for launch! Latent-Y is coming to the Latent Labs Platform, available to researchers worldwide with a free daily quota. Designing an antibody from scratch used to take a specialist team weeks. Soon any researcher will do it in an afternoon, from a plain-language prompt.

00:00